Spectral AI Expands AI-Driven Burn Assessment Technology to Australia

Spectral AI Brings AI-Powered Burn Assessment to Australia

Spectral AI (NASDAQ: MDAI), a Dallas-based predictive AI company, has announced the successful installation of three DeepView® System devices in Australian hospitals. This marks a significant expansion of the company's AI-driven burn wound assessment technology beyond North America 1

1

2

DeepView System: AI-Powered Burn Assessment

The DeepView® System, which received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2018, utilizes multi-spectral imaging and AI algorithms to predict burn healing potential. This non-invasive, cart-based device offers clinicians an immediate and objective assessment of a burn wound's healing potential prior to treatment 1

1

Key Features of the DeepView System:

1. Utilizes a proprietary database of over 340 billion clinically validated data points
2. Provides immediate, data-driven assessment for improved treatment decisions
3. Aims to enhance patient outcomes and reduce healthcare costs

Australian Deployment and Partnership

Spectral AI partnered with PolyNovo Limited, a global medical device company specializing in burn wound therapy, to facilitate the Australian rollout. The company utilized the Australian Special Access Scheme (SAS) to deploy the DeepView Systems at three hospitals 1

1

1. Concord Repatriation General Hospital in Sydney
2. Royal Adelaide Hospital in Adelaide
3. Fiona Stanley Hospital in Murdoch (Perth)

Clinical Perspective and Future Implications

Professor Peter Maitz, Director of the Burn Unit at Concord Repatriation General Hospital, expressed enthusiasm about the technology's potential to enhance patient care and improve outcomes in burn treatment 1

1

2

Dr. J. Michael DiMaio, Chairman of the Board at Spectral AI, highlighted the significance of these real-world device trials in demonstrating the transformative impact of AI in burn wound care. He noted that the company is now operating on two continents, gaining valuable real-world experience that will support their upcoming FDA submission 1

1

Related Stories

Spectral AI Expands Clinical Trial Sites and Strengthens Patent Portfolio

Spectral AI Advances Burn Study with Expanded Clinical Trial Sites and Increased Patient Enrollment

Spectral AI Unveils Advanced AI-Powered Burn Measurement Technology

Spectral AI Announces Q4 and Full Year 2024 Financial Results Conference Call

Company Background and Vision

Spectral AI focuses on developing medical diagnostics for faster and more accurate treatment decisions in wound care. Their initial applications involve patients with burns and diabetic foot ulcers. The company aims to revolutionize wound care management through its "Seeing the Unknown®" approach with the DeepView® System 1

1

2

Market Impact and Future Outlook

While specific financial details were not disclosed, the expansion into the Australian market represents a significant step in Spectral AI's global commercialization strategy. The company's stock (NASDAQ: MDAI) was reported at $1.49, showing a 4.49% decrease, indicating potential market reactions to this news 2

2

As Spectral AI continues to gather real-world data and clinician feedback from these installations, it moves closer to its goal of transforming burn wound care on a global scale. The company's progress in Australia will likely inform its strategies for further international expansion and upcoming regulatory submissions.